Table 1.
Characteristics | EGFR | ALK | ||||
---|---|---|---|---|---|---|
Wild-type | Mutant-type | P value | Wild-type | Mutant-type | P value | |
Age, years | 0.390 | < 0.001 | ||||
Median | 61 | 60 | 61 | 54 | ||
Range | 23–88 | 31–86 | 23–88 | 27–81 | ||
Gender | < 0.001 | 0.337 | ||||
Female | 495 (72.37) | 321 (41.15) | 783 (56.01) | 33 (50.00) | ||
Male | 189 (27.63) | 459 (58.85) | 615 (43.99) | 33 (50.00) | ||
Smoking history | < 0.001 | 0.121 | ||||
Never-smoker | 345 (50.51) | 635 (81.41) | 930 (66.57) | 50 (75.76) | ||
Ever-smoker | 338 (49.49) | 145 (18.59) | 467 (33.43) | 16 (24.24) | ||
Pathology | < 0.001 | 0.036 | ||||
Adenocarcinoma | 585 (85.53) | 753 (96.54) | 1273 (91.06) | 65 (98.48) | ||
Non-adenocarcinoma | 99 (14.47) | 27 (3.46) | 125 (8.94) | 1 (1.52) | ||
AFP | 0.104 | 1.000 | ||||
Negative | 538 (98.18) | 642 (99.23) | 1126 (98.69) | 54 (100.00) | ||
Positive | 10 (1.82) | 5 (0.77) | 15 (1.31) | 0 (0.00) | ||
CEA | 0.014 | 0.060 | ||||
Negative | 341 (50.52) | 342 (44.07) | 645 (46.54) | 38 (58.46) | ||
Positive | 334 (49.48) | 434 (55.93) | 741 (53.46) | 27 (41.54) | ||
CA125 | < 0.001 | 0.164 | ||||
Negative | 319 (48.41) | 458 (59.87) | 748 (54.96) | 29 (46.03) | ||
Positive | 340 (51.59) | 307 (40.13) | 613 (45.04) | 34 (53.97) | ||
CA19-9 | 0.031 | 0.530 | ||||
Negative | 493 (75.61) | 610 (80.37) | 1055 (78.32) | 48 (75.00) | ||
Positive | 159 (24.39) | 149 (19.63) | 292 (21.68) | 16 (25.00) | ||
CA15-3 | 0.195 | < 0.001 | ||||
Negative | 451 (75.04) | 542 (78.10) | 962 (77.64) | 31 (55.36) | ||
Positive | 150 (24.96) | 152 (21.90) | 277 (22.36) | 25 (44.64) | ||
FERR | < 0.001 | 0.135 | ||||
Negative | 210 (55.56) | 289 (68.16) | 471 (61.65) | 28 (73.68) | ||
Positive | 168 (44.44) | 135 (31.84) | 293 (38.35) | 10 (26.32) | ||
CA72-4 | 0.010 | 0.209 | ||||
Negative | 289 (72.43) | 369 (79.87) | 630 (76.83) | 28 (68.29) | ||
Positive | 110 (27.57) | 93 (20.13) | 190 (23.17) | 13 (31.71) | ||
PSA | 0.610 | 0.711 | ||||
Negative | 262 (91.93) | 165 (93.22) | 403 (92.22) | 24 (96.00) | ||
Positive | 23 (8.07) | 12 (6.78) | 34 (7.78) | 1 (4.00) | ||
FPSA | 0.436 | 1.000 | ||||
Negative | 272 (95.44) | 166 (93.79) | 414 (94.74) | 24 (96.00) | ||
Positive | 13 (4.56) | 11 (6.21) | 23 (5.26) | 1 (4.00) | ||
SCC | < 0.001 | 0.178 | ||||
Negative | 472 (76.62) | 636 (90.34) | 1063 (84.23) | 45 (77.59) | ||
Positive | 144 (23.38) | 68 (9.66) | 199 (15.77) | 13 (22.41) | ||
CYFRA 21-1 | < 0.001 | 0.137 | ||||
Negative | 216 (35.64) | 332 (47.91) | 519 (41.75) | 29 (51.79) | ||
Positive | 390 (64.36) | 361 (52.09) | 724 (58.25) | 27 (48.21) | ||
NSE | 0.034 | 0.472 | ||||
Negative | 212 (44.17) | 268 (50.85) | 460 (47.92) | 20 (42.55) | ||
Positive | 268 (55.83) | 259 (49.15) | 500 (52.08) | 27 (57.45) | ||
TTF-1 | < 0.001 | 0.145 | ||||
Negative | 129 (20.48) | 14 (2.04) | 140 (11.13) | 3 (5.08) | ||
Positive | 501 (79.52) | 673 (97.96) | 1118 (88.87) | 56 (94.92) | ||
Napsin A | < 0.001 | 0.401 | ||||
Negative | 121 (28.67) | 19 (5.23) | 135 (18.10) | 5 (12.82) | ||
Positive | 301 (71.33) | 344 (94.77) | 611 (81.90) | 34 (87.18) | ||
CK-7 | 0.006 | 1.000 | ||||
Negative | 19 (5.79) | 3 (1.27) | 21 (3.94) | 1 (3.13) | ||
Positive | 309 (94.21) | 234 (98.73) | 512 (96.06) | 31 (96.88) | ||
Ki67 | 0.083 | 0.528 | ||||
Negative | 37 (28.03) | 28 (40.00) | 60 (31.58) | 5 (41.67) | ||
Positive | 95 (71.97) | 42 (60.00) | 130 (68.42) | 7 (58.33) |
Values presented are n (%) unless otherwise noted
EGFR epidermal growth factor receptor; ALK anaplastic lymphoma kinase; AFP alpha fetoprotein; CEA carcinoembryonic antigen; CA carbohydrate antigen; FERR ferritin; PSA prostate specific antigen; FPSA free prostate specific antigen; SCC squamous cell carcinoma antigen; CYFRA 21-1 soluble fragment of cytokeratin 19; NSE neuron-specific enolase; TTF-1 thyroid transcription factor-1; CK-7 cytokeratin-7